Scholar Rock Holding Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

David Hallal

Chief executive officer

US$400.8k

Total compensation

CEO salary percentage	n/a
CEO tenure	7.8yrs
CEO ownership	0.3%
Management average tenure	1.3yrs
Board average tenure	9.7yrs

Recent management updates

Recent updates

CEO

David Hallal (58 yo)

7.8yrs

Tenure

US$400,849

Compensation

Mr. David L. Hallal is Co-Founder of ElevateBio, LLC and has been its Executive Chairman since April 2025. He served as Chairman and Chief Executive Officer of ElevateBio LLC until April 2025. He is CEO of...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Hallal	CEO & Chairman of the Board	no data	US$400.85k	0.31% € 7.8m
Mo Qatanani	Chief Scientific Officer	1.3yrs	US$2.96m	0.021% € 541.7k
Akshay Vaishnaw	President of R&D	less than a year	US$281.26k	0.010% € 252.8k
Jing Marantz	Chief Medical Officer	2.5yrs	US$3.08m	0.013% € 335.8k
Vikas Sinha	Chief Financial Officer	less than a year	no data	no data
Robert Woods	Chief Operating Officer	less than a year	no data	no data
Erin Moore	Interim Principal Financial & Accounting Officer	5.6yrs	no data	0.087% € 2.2m
Rushmie Nofsinger	Vice President of Corporate Affairs & Investor Relations	no data	no data	no data
Junlin Ho	General Counsel & Corporate Secretary	5.2yrs	US$2.13m	0.10% € 2.6m
Caryn Parlavecchio	Chief Human Resources Officer	3.8yrs	no data	0.062% € 1.6m
Edward Myles	Senior Advisor	less than a year	US$2.01m	0% € 0
Lisa Price	Senior Vice President of Human Resources	no data	no data	no data

1.3yrs

Average Tenure

54yo

Average Age

Experienced Management: 2QK's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
David Hallal	CEO & Chairman of the Board	7.8yrs	US$400.85k	0.31% € 7.8m
Akshay Vaishnaw	President of R&D	11.3yrs	US$281.26k	0.010% € 252.8k
Michael Gilman	Independent Director & Member of Scientific Advisory Board	11.5yrs	US$283.35k	0.039% € 1.0m
Timothy Springer	Member of Scientific Advisory Board	no data	US$48.97k	no data
Jeffrey Flier	Independent Director & Member of Scientific Advisory Board	8.6yrs	US$288.76k	0.0095% € 240.9k
Leonard Zon	Member of Scientific Advisory Board	no data	no data	no data
Daniel Rifkin	Member of Scientific Advisory Board	no data	no data	no data
Kristina Burow	Independent Director	10.8yrs	US$282.94k	0.0056% € 142.7k
Joan Massague	Member of Scientific Advisory Board	no data	no data	no data
Scott L. Friedman	Member of Scientific Advisory Board	no data	no data	no data
Barry Coller	Member of Scientific Advisory Board	no data	no data	no data
Joshua Reed	Independent Director	4.2yrs	US$288.76k	0% € 0

9.7yrs

Average Tenure

65yo

Average Age

Experienced Board: 2QK's board of directors are considered experienced (9.7 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/20 17:25
End of Day Share Price	2025/05/20 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Scholar Rock Holding Corporation is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Madhu Kumar	Baird
Etzer Darout	BMO Capital Markets Equity Research
Guyn Kim	BMO Capital Markets Equity Research

Scholar Rock Holding Management

Management criteria checks 3/4

Key information

Recent management updates

Scholar Rock Appoints Vikas Sinha as Chief Financial Officer

Scholar Rock Holding Corporation, Annual General Meeting, May 22, 2025

Scholar Rock Holding Corporation Announces Executive Changes

Scholar Rock Holding Corporation Announces Executive Changes

Scholar Rock Announces the Appointment of Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Recent updates

Scholar Rock Appoints Vikas Sinha as Chief Financial Officer

FDA Grants Priority Review for Biologics License Application (BLA) and Ema Accepts Marketing Authorisation Application (MAA) for Apitegromab as A Treatment for Spinal Muscular Atrophy

Scholar Rock Holding Corporation, Annual General Meeting, May 22, 2025

Scholar Rock Holding Corporation Announces Executive Changes

Scholar Rock Holding Corporation Announces Executive Changes

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock Announces the Appointment of Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

New major risk - Financial position

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

New major risk - Financial position

President recently sold €170k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Senior VP & Head of Research recently sold €268k worth of stock

New major risk - Revenue and earnings growth

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: US$2.26 loss per share (vs US$3.59 loss in FY 2021)

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock Announces Chief Executive Officer Changes

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Scholar Rock Holding Corporation Provides Pipeline Updates

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.76 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022

Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020)

Scholar Rock Holding Corporation Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.65 loss in 2Q 2020)

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress

Forecast to breakeven in 2025

Scholar Rock Announces Oral Presentation of TOPAZ Phase 2 Trail Results at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy

Scholar Rock Holding Corporation to Present Trials in Progress Poster for Srk-181 Dragon Phase 1 Clinical Trial At the American Society of Clinical Oncology Annual Meeting

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.76 loss per share (vs US$0.58 loss in 1Q 2020)

Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in Therapy

Scholar Rock Announces the Addition of Joshua Reed to Its Board of Directors

Full year 2020 earnings released: US$2.81 loss per share (vs US$1.85 loss in FY 2019)

Revenue misses expectations

New 90-day high: €50.00

Scholar Rock Announces Executive Promotions

New 90-day high: €47.40

New 90-day high: €43.80

Third quarter 2020 earnings released: US$0.79 loss per share

Revenue misses expectations

New 90-day high: €31.80

Scholar Rock Holding Corporation to Report Q2, 2020 Results on Aug 07, 2020